APA (7th ed.) Citation

Wanner, C., Inzucchi, S. E., Zinman, B., Koitka-Weber, A., Mattheus, M., George, J. T., . . . Hauske, S. J. (2020). Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial. Diabetes, obesity and metabolism, 22(12), . https://doi.org/10.1111/dom.14158

Chicago Style (17th ed.) Citation

Wanner, Christoph, Silvio E. Inzucchi, Bernard Zinman, Audrey Koitka-Weber, Michaela Mattheus, Jyothis T. George, Maximilian von Eynatten, and Sibylle J. Hauske. "Consistent Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Irrespective of Diabetic Kidney Disease Categories: Insights from the EMPA-REG OUTCOME Trial." Diabetes, Obesity and Metabolism 22, no. 12 (2020). https://doi.org/10.1111/dom.14158.

MLA (9th ed.) Citation

Wanner, Christoph, et al. "Consistent Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Irrespective of Diabetic Kidney Disease Categories: Insights from the EMPA-REG OUTCOME Trial." Diabetes, Obesity and Metabolism, vol. 22, no. 12, 2020, https://doi.org/10.1111/dom.14158.